PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status.
The novel agent PRIMA-1(met) can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1(met) as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1(met) may therefore act independently of MTp53 status and WTp53 transactivation.
Supiot
Stéphane
S
Princess Margaret Hospital (University Health Network), Toronto, Canada.
Zhao
Helen
H
Wiman
Klas
K
Hill
Richard P
RP
Bristow
Robert G
RG
D001372:Aza Compounds / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D045744:Cell Line, Tumor; D006801:Humans; D000860:Hypoxia; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011836:Radiation Tolerance / Q000187:drug effects; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D001372:Aza Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D011838:Radiation-Sensitizing Agents; D016159:Tumor Suppressor Protein p53; C451219:2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one